Nivolumab Reduces Oral Cancer Risk in Phase I Trial

nivolumab, oral dysplasia, precancerous oral lesions, immunotherapy, checkpoint inhibitors, PD-1 inhibitor, oral cancer prevention, intralesional therapy, AACR 2026, head and neck oncology, cancer immunology, clinical trials oncology, MD Anderson research, minimally invasive oncology, tumor microenvironment, MD Anderson study, tumor immune response, CD8 T cell activation, non surgical cancer treatment, early cancer intervention, oncology clinical trial results

Key Highlights

Intralesional nivolumab reduced lesion size in 85% of patients
60% average shrinkage; 65% saw >50% reduction
41% showed downgraded dysplasia; complete response in some cases
Minimal toxicity compared to systemic immunotherapy
Potential to reduce the need for repeated oral surgeries

Can Low-Dose Nivolumab Prevent Oral Cancer Progression?

A first-in-human Phase I trial presented at the AACR Annual Meeting 2026 has highlighted a promising non-surgical strategy for managing precancerous oral lesions. Researchers from MD Anderson Cancer Center demonstrated that direct intralesional injections of low-dose nivolumab significantly reduced lesion size and progression risk.

Unlike systemic delivery, which exposes patients to higher toxicity, this localized approach used only 2–4% of the standard dose. Patients received weekly injections for four weeks, targeting high-risk oral dysplasia. After a median follow-up of 14.5 months, the majority experienced meaningful clinical improvement.

Importantly, surgery, currently the standard of care, was avoided in most cases. This is particularly relevant as repeated resections often impair speech, swallowing, and overall quality of life.

How Effective Is Intralesional Immunotherapy for Oral Dysplasia?

The trial outcomes suggest strong clinical benefit:

85% of patients had measurable lesion shrinkage
19 patients achieved >50% reduction
12 patients showed histological downgrading
6 patients reached a complete pathological response

Only six lesions progressed to cancer, all detected early and managed surgically. No dose-limiting toxicities were reported, and adverse effects remained mild (Grade 1–2).

From an immunological perspective, treated lesions showed increased infiltration of CD4+ and CD8+ T cells, clear evidence of antitumor immune activation. Blood drug levels remained minimal, confirming reduced systemic exposure.

This targeted delivery ensures high bioavailability directly within the lesion, addressing a major limitation of intravenous immunotherapy.

What Does This Mean for Cancer Prevention Strategies?

Current management of oral dysplasia relies heavily on surgical excision, often repeated due to recurrence and multifocal disease. This study introduces a tissue-preserving alternative that aligns with patient-centered care.

The implications extend beyond oral oncology. Similar precancerous pathways exist in skin, cervical, and colorectal cancers, suggesting broader applicability of localized immunotherapy.

A Phase II trial is planned to assess multi-lesion treatment and validate long-term outcomes. If confirmed, this approach could reshape preventive oncology by reducing invasive procedures while maintaining efficacy.

Nivolumab for Precancerous Oral Lesions Signals a Shift in Prevention

The Phase I findings underscore how nivolumab for precancerous oral lesions can reduce lesion burden, limit progression, and help many patients avoid repeated surgeries. This localized immunotherapy approach offers a clinically relevant path toward tissue preservation and improved quality of life, especially in patients without invasive cancer.